Clene Inc. Form 8-K Summary
Business Context and Reporting Period
Clene Inc. filed a Form 8-K dated April 3, 2024, reporting entry into a grant subaward agreement related to an NIH-funded Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis (ALS). The agreement was entered into by Clene Nanomedicine, Inc., a wholly owned subsidiary, and the university serving as prime awardee under the NIH grant.
Material Agreement and Financial Terms
- The underlying NIH grant is a four-year award totaling $45.1 million and supports the ALS Expanded Access Program under the Accelerating Access to Critical Therapies for ALS Act.
- The subaward provides reimbursement of up to $7.3 million for Clene’s program expenses incurred from September 25, 2023 through August 31, 2024.
- Reimbursement is contingent on Clene submitting invoices monthly or quarterly.
- Aggregate subawards to Clene under the NIH grant may total up to $30.9 million, inclusive of the $7.3 million subaward, and may extend through August 31, 2027. Future amounts are subject to additional agreements or addenda.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other period-specific financial statement metrics.
Material Changes, Outlook, and Risks
- The subaward formalizes Clene’s participation and reimbursement rights under the previously announced NIH grant.
- Either party may terminate the subaward with 30 days’ written notice. If the NIH terminates the underlying grant, the subaward will also be terminated in accordance with NIH requirements.
- Funding is reimbursement-based and therefore depends on eligible expenses, invoice submissions, and continued availability of the NIH grant.
- Clene may use certain background intellectual property developed before the subaward. The agreement does not grant licenses to that background intellectual property to the university or the U.S. government, and Clene is not required to provide proprietary data until satisfactory confidentiality safeguards are agreed.
- The filing provides no new clinical efficacy, regulatory approval, commercial launch, or broader corporate financial guidance.
Key Facts for Investors to Verify
- Whether Clene ultimately receives the full $7.3 million reimbursement and any additional subawards up to the $30.9 million aggregate potential.
- The timing and amount of expenses submitted and reimbursed under the Expanded Access Program.
- Whether the NIH grant remains active through its potential August 31, 2027 extension period.
- Any future agreements or addenda governing additional subawards.
- Any termination notices, changes to intellectual-property protections, or developments affecting the CNM-Au8 ALS program.